Back to Journals » Cancer Management and Research » Volume 9

New developments in the management of Waldenström macroglobulinemia

Authors Abeykoon JP, Yanamandra U, Kapoor P

Received 30 September 2016

Accepted for publication 29 January 2017

Published 10 March 2017 Volume 2017:9 Pages 73—83


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Kenan Onel

Jithma P Abeykoon,1 Uday Yanamandra,2 Prashant Kapoor1,3

1Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA; 2Department of Hematology and Stem Cell Transplant, Army Hospital (Research & Referral), Delhi, India; 3Division of Hematology, Mayo Clinic, Rochester, MN, USA

Abstract: Waldenström macroglobulinemia (WM) is a rare, immunoglobulin M -associated lymphoplasmacytic lymphoma. With the recent discoveries of CXCR warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) and MYD88 mutations, our understanding of the biology of WM has expanded substantially. While WM still remains incurable, the field is rapidly evolving, and a number of promising agents with significant activity in this malignancy are being evaluated currently. In this review, we discuss the new developments that have occurred in WM over the past 15 years, with a focus on the role of ibrutinib, an oral Bruton’s tyrosine kinase inhibitor that has recently been approved for WM in the United States, Europe, and Canada.

Keywords: lymphoplasmacytic lymphoma, indolent lymphoma, MYD88, CXCR4, management, ibrutinib

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]